Castle Biosciences, Inc. (NASDAQ:CSTL) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) have received a consensus recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $43.1667.

Several analysts recently commented on CSTL shares. Zacks Research cut shares of Castle Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 2nd. BTIG Research increased their target price on shares of Castle Biosciences from $38.00 to $50.00 and gave the company a “buy” rating in a report on Friday, December 12th. Weiss Ratings reissued a “sell (d)” rating on shares of Castle Biosciences in a research note on Monday, December 29th. Guggenheim upped their price target on Castle Biosciences from $30.00 to $43.00 and gave the stock a “buy” rating in a report on Monday. Finally, Robert W. Baird raised their price objective on Castle Biosciences from $39.00 to $41.00 and gave the company an “outperform” rating in a research note on Tuesday, November 4th.

Insider Buying and Selling at Castle Biosciences

In related news, insider Derek J. Maetzold sold 830 shares of the stock in a transaction dated Monday, December 22nd. The shares were sold at an average price of $40.35, for a total value of $33,490.50. Following the sale, the insider directly owned 33,530 shares of the company’s stock, valued at approximately $1,352,935.50. This represents a 2.42% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Kristen M. Oelschlager sold 14,888 shares of the firm’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $39.31, for a total transaction of $585,247.28. Following the transaction, the chief operating officer owned 12,323 shares of the company’s stock, valued at $484,417.13. This trade represents a 54.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 50,764 shares of company stock valued at $1,701,145. Insiders own 7.20% of the company’s stock.

Institutional Trading of Castle Biosciences

Several institutional investors and hedge funds have recently modified their holdings of CSTL. Farther Finance Advisors LLC increased its stake in shares of Castle Biosciences by 139,100.0% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,392 shares of the company’s stock worth $32,000 after purchasing an additional 1,391 shares in the last quarter. State of Alaska Department of Revenue acquired a new stake in Castle Biosciences during the 3rd quarter valued at $35,000. CWM LLC grew its holdings in Castle Biosciences by 80.6% during the 3rd quarter. CWM LLC now owns 1,911 shares of the company’s stock valued at $44,000 after buying an additional 853 shares during the last quarter. Russell Investments Group Ltd. increased its position in Castle Biosciences by 63.7% during the third quarter. Russell Investments Group Ltd. now owns 2,508 shares of the company’s stock worth $57,000 after buying an additional 976 shares in the last quarter. Finally, Jones Financial Companies Lllp raised its holdings in shares of Castle Biosciences by 10,592.0% in the first quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock worth $54,000 after acquiring an additional 2,648 shares during the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Castle Biosciences Stock Up 2.7%

Castle Biosciences stock opened at $40.07 on Wednesday. The stock’s 50 day moving average price is $36.73 and its 200 day moving average price is $26.50. Castle Biosciences has a 1-year low of $14.59 and a 1-year high of $42.17. The company has a market cap of $1.17 billion, a PE ratio of -89.04 and a beta of 1.06. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.47 and a quick ratio of 6.31.

Castle Biosciences (NASDAQ:CSTL) last released its quarterly earnings data on Monday, November 3rd. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.32. The firm had revenue of $80.55 million during the quarter, compared to analysts’ expectations of $71.06 million. Castle Biosciences had a positive return on equity of 1.73% and a negative net margin of 3.56%. On average, sell-side analysts predict that Castle Biosciences will post 0.44 EPS for the current fiscal year.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.